Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III StudyWOS

    Yang Jing
    Yang Jing
    Wang Linda
    Wang Linda
    Kottakis Ioannis
    Kottakis Ioannis
    Humphries Michael
    Humphries Michael
    null null
    null null
    Cited by: 24|Bibtex|13|

    Allergy, asthma & immunology research, Volume 8, Issue 4, 2016, Pages 319-328.

    Keywords:
    AsthmaChinaallergy and immunologyomalizumabquality of life

    Abstract:

    Omalizumab is the preferred add-on therapy for patients with moderate-to-severe persistent allergic asthma and has demonstrated efficacy and safety in various ethnicities. This study evaluated the efficacy and safety of omalizumab in Chinese patients with moderate-to-severe allergic asthma.This randomized, double-blind, parallel-group, pl...More
    Your rating :
    0

     

    Tags
    Comments